Overview
The marketing authorisation for Clopidogrel Dura has been withdrawn at the request of the marketing authorisation holder.
Clopidogrel DURA : EPAR - Summary for the public
English (EN)
(500.91 KB - PDF)View
български (BG)
(666.03 KB - PDF)
español (ES)
(502.83 KB - PDF)
čeština (CS)
(640.33 KB - PDF)
dansk (DA)
(502.77 KB - PDF)
Deutsch (DE)
(503.53 KB - PDF)
eesti keel (ET)
(501.87 KB - PDF)
ελληνικά (EL)
(676.7 KB - PDF)
français (FR)
(503.27 KB - PDF)
italiano (IT)
(44.12 KB - PDF)
latviešu valoda (LV)
(640.76 KB - PDF)
lietuvių kalba (LT)
(612.64 KB - PDF)
magyar (HU)
(631.46 KB - PDF)
Malti (MT)
(641.86 KB - PDF)
Nederlands (NL)
(502.6 KB - PDF)
polski (PL)
(646.38 KB - PDF)
português (PT)
(502.72 KB - PDF)
română (RO)
(606.6 KB - PDF)
slovenčina (SK)
(637.55 KB - PDF)
slovenščina (SL)
(596.03 KB - PDF)
Suomi (FI)
(501.85 KB - PDF)
svenska (SV)
(502.3 KB - PDF)
Product information
Clopidogrel DURA : EPAR - Product Information
English (EN)
(807.47 KB - PDF)View
български (BG)
(1.47 MB - PDF)
español (ES)
(809.59 KB - PDF)
čeština (CS)
(1.18 MB - PDF)
dansk (DA)
(735.62 KB - PDF)
Deutsch (DE)
(735.69 KB - PDF)
eesti keel (ET)
(745.43 KB - PDF)
ελληνικά (EL)
(1.59 MB - PDF)
français (FR)
(767.22 KB - PDF)
hrvatski (HR)
(808.15 KB - PDF)
íslenska (IS)
(1.28 MB - PDF)
italiano (IT)
(784.52 KB - PDF)
latviešu valoda (LV)
(1.25 MB - PDF)
lietuvių kalba (LT)
(844.95 KB - PDF)
magyar (HU)
(1.2 MB - PDF)
Malti (MT)
(1.17 MB - PDF)
Nederlands (NL)
(797.49 KB - PDF)
norsk (NO)
(1.26 MB - PDF)
polski (PL)
(1.21 MB - PDF)
português (PT)
(758.64 KB - PDF)
română (RO)
(910.9 KB - PDF)
slovenčina (SK)
(1.16 MB - PDF)
slovenščina (SL)
(1.1 MB - PDF)
Suomi (FI)
(749.08 KB - PDF)
svenska (SV)
(761.91 KB - PDF)
Latest procedure affecting product information: R/0017
05/05/2015
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Clopidogrel DURA : EPAR - All Authorised presentations
English (EN)
(480.5 KB - PDF)View
български (BG)
(552.25 KB - PDF)
español (ES)
(468.04 KB - PDF)
čeština (CS)
(505.21 KB - PDF)
dansk (DA)
(464.31 KB - PDF)
Deutsch (DE)
(463.9 KB - PDF)
eesti keel (ET)
(468.06 KB - PDF)
ελληνικά (EL)
(551.22 KB - PDF)
français (FR)
(467.73 KB - PDF)
italiano (IT)
(467.26 KB - PDF)
latviešu valoda (LV)
(562.34 KB - PDF)
lietuvių kalba (LT)
(535.75 KB - PDF)
magyar (HU)
(547.89 KB - PDF)
Malti (MT)
(544.46 KB - PDF)
Nederlands (NL)
(465.85 KB - PDF)
polski (PL)
(510.52 KB - PDF)
português (PT)
(483.58 KB - PDF)
română (RO)
(531.12 KB - PDF)
slovenčina (SK)
(524.92 KB - PDF)
slovenščina (SL)
(480.14 KB - PDF)
Suomi (FI)
(467.29 KB - PDF)
svenska (SV)
(483.56 KB - PDF)
Product details
- Name of medicine
- Clopidogrel DURA
- Active substance
- clopidogrel (as hydrochloride)
- International non-proprietary name (INN) or common name
- clopidogrel
- Therapeutic area (MeSH)
- Peripheral Vascular Diseases
- Stroke
- Myocardial Infarction
- Anatomical therapeutic chemical (ATC) code
- B01AC04
Pharmacotherapeutic group
Antithrombotic agentsTherapeutic indication
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
Assessment history
Clopidogrel DURA : EPAR - Procedural steps taken and scientific information after authorisation
English (EN)
(594.33 KB - PDF)View
This page was last updated on